None
Quote | Oragenics Inc. (NYSE:OGEN)
Last: | $1.08 |
---|---|
Change Percent: | 5.56% |
Open: | $1.02 |
Close: | $1.08 |
High: | $1.135 |
Low: | $1.015 |
Volume: | 71,800 |
Last Trade Date Time: | 04/17/2024 03:00:00 am |
News | Oragenics Inc. (NYSE:OGEN)
2024-04-01 10:02:27 ET More on Oragenics Oragenics stock dips after pricing $2.1M stock offering Financial information for Oragenics Read the full article on Seeking Alpha For further details see: Oragenics files 10K and provides company update
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has execu...
Message Board Posts | Oragenics Inc. (NYSE:OGEN)
Subject | By | Source | When |
---|---|---|---|
Maybe not. :) | retired early | investorshub | 03/01/2023 6:46:26 PM |
Don't madder they will short it down to nothing | Nathan123456 | investorshub | 12/22/2022 10:32:36 PM |
Surfs up. ::) | retired early | investorshub | 12/22/2022 2:35:47 PM |
Chart setup perfectly here -> time is koming | BEIJING BILL | investorshub | 08/17/2022 4:51:49 PM |
Hey whatever it takes to see it rise | retired early | investorshub | 05/27/2022 5:06:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has execu...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II ...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it is preparing to undertake the final steps of GMP manufacturing and formulation of its drug candidate for its expected Phase IIA...